Description

Vencomax BRONQ

Manufactured by: Vencopharma (Venco Animal Health)

Dosage form: Injectable vaccine

Presentation: 

Flow pack with 20 (1.0 ml x 20) individual doses.

Ingredients & Composition:

Per dose of 1.0 ml Vencomax BRONQ vaccine contains inactivated Bordetella bronchiseptica.

Description / Action: 

Vencomax BRONQ is an inactivated monovalent vaccine against kennel cough which promotes immunity against Bordetella bronchiseptica, a bacterium involved in the most serious cases of Dogs’ coughing. If it is not avoided, it might evolve to a bronchopneumonia. Vencomax BRONQ provides protection against the most serious coughing agent/ Canine Infectious Tracheobronchitis in dogs.

Canine Cough has a high risk in Dogs which are used to attend pet shops, hotels, fairs, immunosuppressed dogs, dogs going through chemotherapy, and Kennel’s animals. Environmental factors such as cold,  kennel arrangement, and humidity are common conditions that increase the susceptibility of the disease. Kennel cough symptoms include severe and dry cough (aggravated by activity or excitement); vomiting and effort in trying to expel mucus from the upper respiratory tract and fever. The best way to prevent this disease is through vaccination.

Class: Biologicals / Dog Vaccine

Indication / Uses:

Vencomax BRONQ is indicated for active immunization of healthy dogs and puppies against

• • Bordetella bronchiseptica

Resulting in the prevention of Kennel Cough disease.

Dosage and administration:

The dose is 1 mL, intramuscularly or subcutaneously, regardless of race or weight.

Vaccination Programme:

The vaccine can be used from 45 days of age and it´s recommended a 2nd and 3rd dose, with an interval of 30 days between them and should be repeated annually to have a better immune response.

Unvaccinated adult animals: 2 doses with 21 days of interval between them. Revaccinate annually.

Better tranquility and safety at the application:  Application route SC or IM better tolerated by the animals and more preference by the Veterinarians. Through this route, the chance to lose a product during the application is smaller, infact which occurs more frequently at the intranasal, after the animal’s sneezing.

The study has pointed out that the subcutaneous vaccines promote better levels of IgG in seropositive dogs than the intranasal vaccines.

Overdoses / Side effects / Contraindications /Warnings:

Strictly avoid mixing of Vencomax BRONQ with other vaccines. Like other vaccines, anaphylactic or hypersensitivity reactions may occur which can be treated accordingly.

Pharmaceutical precautions / Instructions: 

The vaccine must be stored in the original container between 2 °C and 8 °C. Protect from light. Do not freeze.

Safety: Age / Pregnancy/ Withdrawal:

Safe and with no risk of virulence reversion. The parenteral vaccine provides good pulmonary protection and higher levels of IgG and the intranasal vaccine induces higher local immunity (secretory IgA and cellular immunity), with the possibility of the products being associated at the same time or in diff erent times of the animal’s life, ensuring even more complete protection.

Vencomax BRONQ intranasal vaccine is safe for use in puppies from 45 days of age.  Safety in pregnant and lactating animals has not been stated by the manufacturer. Vaccinate healthy puppies or dogs only.

Habit forming:  No, But Protocol should be followed according to the guidelines to achieve immunity.

Substitute: Nobivac KC (Intranasal)